Benefits
Subclinical Depression / Low Mood (Major 2025 Trial)
Lopresti 2025 RCT (n=202, the largest saffron antidepressant trial to date) showed Affron® 28 mg/day reduced depression scores 53% vs 39% placebo over 12 weeks; 72% of Affron group achieved clinically significant improvement vs 54% placebo. Published Journal of Nutrition May 2025.
Major Depressive Disorder Adjunct
Multiple Affron® trials show effects in clinical depression. Mechanism via serotonergic and other neurotransmitter pathways.
Mood Enhancement in Healthy Adults
Kell 2017 trial showed Affron® improved mood and stress in healthy adults without depression — 4-week intervention. Suggests broader mood-supportive applications beyond clinical depression.
Sleep Quality (Subset of Patients)
Lopresti 2020 trial showed Affron® improved sleep quality, especially in those with greater baseline sleep disturbance. Mechanism via melatonin pathway modulation suggested.
Adolescent Mental Health
Lopresti 2018 trial in adolescents with anxiety/depressive symptoms showed mood improvements with Affron® 14 mg twice daily.
Menopausal Symptoms (Modest)
Lopresti 2021 trial in perimenopausal women showed Affron® improved psychological symptoms of menopause. Adjunct option for hormonal mood symptoms.
Mechanism of action
Standardized Lepticrosalides® Bioactive Profile
Standardization to 3.5% Lepticrosalides® (Pharmactive's proprietary characterization of saffron's most bioactive compounds) ensures consistent dose-response. Distinguishes from generic saffron extracts with variable composition.
Serotonergic Effects (Same as Generic Saffron)
Crocins and safranal modulate serotonin pathways. Foundation for mood effects.
Neurotrophic / BDNF Support
Animal and translational research supports BDNF increases — neuroplasticity mechanism for sustained mood effects.
Anti-Inflammatory / Neuroprotective
Crocins reduce neuroinflammation — emerging mechanism for mood and cognitive applications.
Clinical trials
RCT of Affron® 28 mg/day vs placebo in 202 adults with subclinical depression for 12 weeks. Published Journal of Nutrition.
202 adults with subclinical depression (largest saffron trial to date).
53% reduction in depression scores vs 39% placebo; 72% achieved clinically significant improvement vs 54% placebo. Established efficacy in subclinical/low-mood populations.
RCT of Affron® 28 mg/day or 22 mg/day vs placebo in 128 healthy adults for 4 weeks.
128 healthy adults with low mood.
Both Affron doses improved mood, stress, and anxiety scores vs placebo. Established efficacy in non-clinical populations.
About this ingredient
AFFRON® is a STANDARDIZED SAFFRON EXTRACT manufactured by PHARMACTIVE BIOTECH PRODUCTS (Spain). Distinguished by: (1) STANDARDIZATION to 3.5% LEPTICROSALIDES® — Pharmactive's proprietary characterization of saffron's most bioactive compounds (crocins, safranal, picrocrocin); (2) PROPRIETARY EXTRACTION PROCESS preserving thermolabile compounds; (3) EXTENSIVE CLINICAL EVIDENCE — 11+ published clinical trials at the time of writing, including the LARGEST SAFFRON ANTIDEPRESSANT TRIAL to date (Lopresti 2025, n=202).
EVIDENCE-BASED USES: (1) SUBCLINICAL DEPRESSION / LOW MOOD — 2025 large-scale trial established efficacy; (2) MAJOR DEPRESSIVE DISORDER (mild-moderate) — multiple trials; (3) MOOD ENHANCEMENT in healthy adults (Kell 2017); (4) Sleep quality (in those with sleep disturbance); (5) ADOLESCENT mental health (Lopresti 2018); (6) MENOPAUSAL psychological symptoms (Lopresti 2021); (7) ADHD adjunct (limited evidence); (8) Anxiety.
CRITICAL CAUTIONS: (1) DOSE — 28 mg/day is research-validated; lower than generic saffron (30 mg/day) due to standardization providing more consistent bioactive content; some trials use 14 mg BID; (2) DURATION — antidepressant effects build over 4-8 weeks; for sustained benefit, continue 12+ weeks; (3) SUBCLINICAL VS CLINICAL DEPRESSION — Affron has evidence in BOTH populations; particularly notable for subclinical/low mood (smaller magnitude condition with limited pharmaceutical options); (4) PREGNANCY — limited specific Affron® safety data; saffron generally cautioned in pregnancy due to historical uterotonic concerns; AVOID supplementation; (5) ANTIDEPRESSANT INTERACTION — theoretical additive serotonergic effects; consult prescriber; saffron has weaker effects than pharmaceuticals so combination risk is modest; (6) STANDARDIZATION ADVANTAGE — generic saffron extracts vary widely in quality; Affron® provides consistent dose-response based on standardized bioactive content; clinically meaningful differentiation; (7) BRAND VERIFICATION — verify products specifying 'Affron®' (Pharmactive trademark); generic saffron without standardization has more variable response; (8) RESEARCH POSITIONING — Affron is among the most-studied branded saffron extracts; competitor branded forms include Saffretine® (separate entry) and Safr'Inside®; all evidence-based; (9) FOR DEPRESSION — Affron is reasonable adjunct or alternative for mild-moderate depression; for severe MDD, pharmaceutical and psychotherapeutic treatment is foundational; (10) FOR HEALTHY MOOD SUPPORT — Affron has unique evidence for mood enhancement in non-clinical populations; reasonable for those seeking mood support without clinical depression diagnosis; (11) SLEEP QUALITY — Affron's sleep effects are evident in those with sleep issues, not universally; bonus benefit but not primary indication; (12) PMS / MENOPAUSE — Affron's hormonal-related mood effects make it particularly useful for these contexts; (13) Affron is one of the most extensively clinically-studied herbal antidepressants — strong evidence for mood applications; reasonable consideration in evidence-based integrative protocols.